Hepatitis B Virus Infection Pipeline Analysis: 80+ Companies are Working to Improve the Treatment Space | DelveInsight

 Breaking News
  • No posts were found

Hepatitis B Virus Infection Pipeline Analysis: 80+ Companies are Working to Improve the Treatment Space | DelveInsight

November 07
21:32 2022
Hepatitis B Virus Infection Pipeline Analysis: 80+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight’s, “Hepatitis B Virus (HBV) Infection- Pipeline Insight, 2022” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hepatitis B Virus (HBV) Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Hepatitis B Virus Infection Pipeline Insight Report

  • DelveInsight’s Hepatitis B Virus Infection Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Hepatitis B Virus Infection.
  • The leading Hepatitis B Virus Infection Companies such as Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Nucorion Pharmaceuticals, Gilead Sciences Dong-A ST Co. Ltd., Assembly Biosciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, Vir Biotechnology, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharma, ISA Pharmaceuticals, Dicerna Pharmaceuticals, and others are evaluating new Hepatitis B Virus Infection drugs to improve the treatment landscape.
  • Promising Hepatitis B Virus Infection Pipeline therapies such as EYP001a, VBR, AB-729, SOC NrtI, VIR-2218, NCO-48 Fumarate 4 mg, HB-AS02V, HBVAXPRO vaccine, ACH-126,443, Lamivudine, entecavir, FENDRIX, and others are under different phases of Hepatitis B Virus Infection clinical trials.
  • In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatitis B Virus (HBV) Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis B Virus (HBV) Infection R&D. The therapies under development are focused on novel approaches to treat/improve Hepatitis B Virus (HBV) Infection.

 

Get an overview of the Hepatitis B Virus Infection Pipeline landscape @ Hepatitis B Virus Infection Emerging Therapies

 

Hepatitis B Virus Infection Overview

Hepatitis means inflammation of the liver. When the liver is inflamed or damaged, its function can be affected. Heavy alcohol use, toxins, some medications, and certain medical conditions can all cause hepatitis. However, hepatitis is often caused by a virus. In the United States, the most common hepatitis viruses are hepatitis A virus, hepatitis B virus, and hepatitis C virus. Hepatitis B is a liver infection caused by the hepatitis B virus. Some people with hepatitis B are sick for only a few weeks (known as “acute” infection), but for others, the disease progresses to a serious, lifelong illness known as chronic hepatitis B. Some people, especially those who get infected in adulthood, are able to clear the virus from their bodies without treatment. For other people, acute hepatitis B leads to life-long infection known as chronic hepatitis B. Over time, chronic hepatitis B can cause serious health problems, including liver damage, cirrhosis, liver cancer, and even death.

 

Latest Breakthroughs of Hepatitis B Virus Infection Treatment Landscape

  • AB-729 is a subcutaneously-delivered RNA interference (RNAi) therapeutic specifically designed to reduce all HBV viral antigens, including hepatitis B surface antigen, which is thought to be a key prerequisite to enable reawakening of a patient’s immune system to respond to the virus.  AB-729 targets hepatocytes using the novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology. AB-729 is currently being evaluated in a Phase 2a randomized, open-label, proof-of-concept clinical trial in combination with ongoing standard-of-care nucleos(t)ide analog therapy and short courses of Peg-IFNα-2a in 40 patients with chronic HBV infection.
  • ABI-H3733 (3733), is an investigational next-generation, highly potent core inhibitor. 3733 has demonstrated significantly increased potency against covalently closed circular DNA (cccDNA) formation and new virus production as compared to first-generation core inhibitors in preclinical studies. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Chronic Hepatitis B virus Infection.
  • VIR-2218 is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.

 

Request a sample and discover the recent advances in Hepatitis B Virus Infection r treatment drugs @ Hepatitis B Virus Infection Pipeline Report

 

Hepatitis B Virus Infection Emerging Drugs

  • VIR 2218: Vir Biotechnology
  • ABI H3733: Assembly Biosciences
  • AB 729: Arbutus Biopharma

 

DelveInsight’s Hepatitis B Virus Infection Pipeline Report covers around 80+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Learn more about the emerging Hepatitis B Virus Infection pipeline therapies @ Hepatitis B Virus Infection Clinical Trials

 

Scope of the Hepatitis B Virus Infection Pipeline Report

  • Coverage- Global
  • Hepatitis B Virus Infection Therapeutic Assessment
  • Hepatitis B Virus Infection Companies- Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Nucorion Pharmaceuticals, Gilead Sciences Dong-A ST Co. Ltd., Assembly Biosciences, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, Vir Biotechnology, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharma, ISA Pharmaceuticals, Dicerna Pharmaceuticals, and others
  • Hepatitis B Virus Infection Drugs- EYP001a, VBR, AB-729, SOC NrtI, VIR-2218, NCO-48 Fumarate 4 mg, HB-AS02V, HBVAXPRO vaccine, ACH-126,443, Lamivudine, entecavir, FENDRIX, and others
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

 

Dive deep into rich insights for new drugs for Hepatitis B Virus Infection treatment, visit @ Hepatitis B Virus Infection Companies

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Hepatitis B Virus (HBV) Infection: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Hepatitis B Virus (HBV) Infection– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Mid Stage Products (Phase II)
  9. AB 729: Arbutus Biopharma
  10. Early Stage Products (Phase I)
  11. ABI H3733: Assembly Biosciences
  12. Preclinical and Discovery Stage Products
  13. Inactive Products
  14. Hepatitis B Virus (HBV) Infection Key Companies
  15. Hepatitis B Virus (HBV) Infection Key Products
  16. Hepatitis B Virus (HBV) Infection- Unmet Needs
  17. Hepatitis B Virus (HBV) Infection- Market Drivers and Barriers
  18. Hepatitis B Virus (HBV) Infection- Future Perspectives and Conclusion
  19. Hepatitis B Virus (HBV) Infection Analyst Views
  20. Hepatitis B Virus (HBV) Infection Key Companies
  21. Appendix

 

For further information on the Hepatitis B Virus Infection pipeline therapeutics, reach out to Hepatitis B Virus Infection Treatment

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Calendar

December 2022
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  

Categories